News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
INSILICO (03696.HK) Rentosertib Inhalation Formulation Receives CDE Clinical Trial Approval
INSILICO (03696.HK) announced that its clinical trial application for the self-developed Rentosertib (ISM001-055) inhalation formulation for the treatment of adult idiopathic pulmo...
Reset
Send
The window will close in 5 seconds
INSILICO (03696.HK) Rentosertib Inhalation Formulation Receives CDE Clinical Trial Approval
Close
Recommend
6
Positive
5
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get Level 1 Real-Time Streaming!

INSILICO (03696.HK)  +1.250 (+1.983%)    Short selling $27.33M; Ratio 30.557%   announced that its clinical trial application for the self-developed Rentosertib (ISM001-055) inhalation formulation for the treatment of adult idiopathic pulmonary fibrosis (IPF) has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China. This marks the 13th project in the Groups AI-driven R&D pipeline to receive clinical trial approval.

The approval supports the initiation of a Phase I clinical study aimed at evaluating the safety, tolerability and pharmacokinetic (PK) profile of the Rentosertib inhalation formulation. The study consists of two parts: the first part is a randomized, double-blind, placebo-controlled trial in healthy subjects, including single ascending dose (SAD) and multiple ascending dose (MAD) cohorts; the second part is a non-randomized, open-label assessment in IPF patients receiving multiple doses. Approximately 80 subjects are expected to be enrolled in total. (ec/w)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-04 16:25.)



This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

Auto-translated by AI
View Original Text

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.